On June 2, 2016, the Company held its 2016 Annual Meeting of Stockholders in Incline Village, Nevada. At the annual meeting, the Companys stockholders: (i) elected each of Harold E. Selick, Ph.D., Paul R. Edick and Samuel R. Saks, M.D. to the Companys Board of Directors for a term of three years, (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2016, and (iii) approved, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Companys 2016 proxy statement.
Represented in person or by proxy at the annual meeting were 142,989,966 shares of the Companys common stock, or 86.6% of the total number of shares outstanding as of the recor d date. The results of the matters submitted to a stockholder vote at the annual meeting were as follows.
1.Election of Directors:
Harold E. Selick, Ph.D.
Paul R. Edick
Samuel R. Saks, M.D.
Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016:
Approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Companys proxy statement:
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PDL BIOPHARMA, INC.
/s/ Christopher Stone
Vice President, General Counsel and Secretary
makes a similar move, sign up!
Other recent filings from the company include the following:
Completion of Acquisition or Disposition of - Sept. 21, 2017
PDL BioPharma's President just picked up 240,200 shares - Sept. 13, 2017
PDL BioPharma's President just declared 0 ownership of the company. - Sept. 13, 2017
Securities to be offered to employees in employee benefit plans - Sept. 12, 2017
Current report, items 7.01 and 9.01 - Sept. 11, 2017